Tumor slice culture system to assess drug response of primary breast cancer

BMC Cancer

Volumn 16, Issue 1, 2016, Pages

  Naipal, Kishan A T ^a   Verkaik, Nicole S ^a   Sánchez, Humberto ^a   van Deurzen, Carolien H M ^a   den Bakker, Michael A ^b   Hoeijmakers, Jan H J ^a   Kanaar, Roland ^a   Vreeswijk, Maaike P G ^c   Jager, Agnes ^a   van Gent, Dik C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Maasstad Hospital Rotterdam   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Breast cancer; Ex vivo sensitivity; FAC chemotherapy; Organotypic tumor tissue slices; Tissue culture method

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL;

ARTICLE; BREAST CANCER; CANCER RESISTANCE; CANCER THERAPY; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; DRUG RESPONSE; DRUG SENSITIVITY; EX VIVO STUDY; HUMAN; HUMAN TISSUE; PERSONALIZED MEDICINE; PRIMARY TUMOR; TISSUE CULTURE TECHNIQUE; TISSUE SLICE; TISSUE STRUCTURE; TUMOR SLICE; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENETICS; PATHOLOGY; PROCEDURES; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLUOROURACIL; HUMANS; PRECISION MEDICINE; TISSUE CULTURE TECHNIQUES; TUMOR CELLS, CULTURED;

EID: 84957889959     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-016-2119-2     Document Type: Article

References (26)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Campos SM, Winer EP. Hormonal therapy in postmenopausal women with breast cancer. Oncology. 2003;64(4):289-99.
3. Burdall SE, Hanby AM, Lansdown MR, Speirs V. Breast cancer cell lines: friend or foe? Breast Cancer Res. 2003;5(2):89-95.
4. Seifert HH, Meyer A, Cronauer MV, Hatina J, Muller M, Rieder H, et al. A new and reliable culture system for superficial low-grade urothelial carcinoma of the bladder. World J Urol. 2007;25(3):297-302.
5. Sato T, Stange DE, Ferrante M, Vries RG, Van Es JH, Van den Brink S, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology. 2011;141(5):1762-72.
6. Vaira V, Fedele G, Pyne S, Fasoli E, Zadra G, Bailey D, et al. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc Natl Acad Sci U S A. 2010;107(18):8352-6.
7. Hidalgo M, Amant F, Biankin AV, Budinska E, Byrne AT, Caldas C, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4(9):998-1013.
8. Failli A, Consolini R, Legitimo A, Spisni R, Castagna M, Romanini A, et al. The challenge of culturing human colorectal tumor cells: establishment of a cell culture model by the comparison of different methodological approaches. Tumori. 2009;95(3):343-7.
9. Speirs V, Green AR, Walton DS, Kerin MJ, Fox JN, Carleton PJ, et al. Short-term primary culture of epithelial cells derived from human breast tumours. Br J Cancer. 1998;78(11):1421-9.
10. Dairkee SH, Deng G, Stampfer MR, Waldman FM, Smith HS. Selective cell culture of primary breast carcinoma. Cancer Res. 1995;55(12):2516-9.
11. Fiebig HH, Neumann HA, Henss H, Koch H, Kaiser D, Arnold H. Development of three human small cell lung cancer models in nude mice. Recent Results Cancer Res. 1985;97:77-86.
12. Houghton JA, Houghton PJ, Green AA. Chemotherapy of childhood rhabdomyosarcomas growing as xenografts in immune-deprived mice. Cancer Res. 1982;42(2):535-9.
13. Gerlach MM, Merz F, Wichmann G, Kubick C, Wittekind C, Lordick F, et al. Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistance. Br J Cancer. 2014;110(2):479-88.
14. Naipal KA, Verkaik NS, Ameziane N, van Deurzen CH, Ter Brugge P, Meijers M, et al. Functional ex vivo assay to select Homologous Recombination deficient breast tumors for PARP inhibitor treatment. Clin Cancer Res. 2014;20(18):4816-26.
15. van der Kuip H, Murdter TE, Sonnenberg M, McClellan M, Gutzeit S, Gerteis A, et al. Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment. BMC Cancer. 2006;6:86.
16. Holliday DL, Moss MA, Pollock S, Lane S, Shaaban AM, Millican-Slater R, et al. The practicalities of using tissue slices as preclinical organotypic breast cancer models. J Clin Pathol. 2013;66(3):253-5.
17. Sanchez H, Wyman C. SFMetrics: an analysis tool for scanning force microscopy images of biomolecules. BMC Bioinformatics. 2015;16:27.
18. Manders EMM, Verbeek FJ, Aten JA. Measurement of co-localization of objects in dual-colour confocal images. J Microsc. 1993;169(3):375-82.
19. Garvin S, Nilsson UW, Huss FR, Kratz G, Dabrosin C. Estradiol increases VEGF in human breast studied by whole-tissue culture. Cell Tissue Res. 2006;325(2):245-51.
20. Pennington K, Chu QD, Curiel DT, Li BD, Mathis JM. The utility of a tissue slice model system to determine breast cancer infectivity by oncolytic adenoviruses. J Surg Res. 2010;163(2):270-5.
21. Martin M, Ruiz A, Ruiz Borrego M, Barnadas A, Gonzalez S, Calvo L, et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study. J Clin Oncol. 2013;31(20):2593-9.
22. Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003;12(5):320-7.
23. van Oijen MG, Medema RH, Slootweg PJ, Rijksen G. Positivity of the proliferation marker Ki-67 in noncycling cells. Am J Clin Pathol. 1998;110(1):24-31.
24. Balmativola D, Marchio C, Maule M, Chiusa L, Annaratone L, Maletta F, et al. Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study. Breast Cancer Res Treat. 2014;148(3):511-23.
25. Akhtar MS, Kousar F, Masood M, Fatimi S, Kokab. Evaluation of paclitaxel and carboplatin versus combination chemotherapy with fluorouracil, doxorubicin and cyclophosphamide as a neoadjuvant therapy in patients with inoperable breast cancer. J Coll Physicians Surg Pak. 2010;20(11):748-52.
26. Gogia A, Raina V, Deo SV, Shukla NK, Mohanti BK, Sharma DN. Taxane and anthracycline based neoadjuvant chemotherapy for locally advanced breast cancer: institutional experience. Asian Pac J Cancer Prev. 2014;15(5):1989-92.